For Health Care Professionals Outside the US

 
 
 

Re-treatment with the same regimen may not be enough1

Even though current guidelines suggest re-treatment for patients who had a good response—re-treatment may not provide a maximum clinical benefit1,2

Multiple myeloma re-treatment and response rates

Data are from PANORAMA 1, a phase 3, randomised, double-blind study and are from the placebo/BTZ/dex arm of the study. The approval of FARYDAK® (panobinostat) regimen was based upon the efficacy and safety in a subgroup analysis of 147 patients (73 in the FARYDAK/BTZ/dex arm and 74 in the placebo/BTZ/dex arm) who had received at least 2 prior regimens, including BTZ and an IMiD.2

How is progression defined?

References:

  1. IMWG guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. International Myeloma Foundation website. http://myeloma.org/ArticlePage.action?tabId=4&menuId=308&articleId=2978&aTab=-1&gParentType=menuitem&gParentId=308&parentIndexPageId=284. Published January 12, 2012. Accessed June 7, 2015.
  2. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; April 2016.